発射分子が保存された心不全における左心房高縮および心筋線維症:メカニズムと治療
Alexander Peikert1, Marianna Fontana2, Scott D Solomon3
1Department of Cardiology, University Heart Center Graz, Medical University of Graz, Graz, Austria.
European heart journal
|September 2, 2025
まとめ
保存されたエジェクション分数 (HFpEF) の心不全は,心筋線維症や高縮などの複雑な特徴を伴う. これらの特徴を標的とした新しい治療法が 患者の改善のために必要である.
科学分野:
- 心臓病科
- 内科 医学
背景:
- 発射分数保存 (HFpEF) による心不全は,心不全症例の大部分を占めています.
- HFpEFは,さまざまな患者フェノタイプと高血圧,肥満,糖尿病などの頻繁な心代謝併発症によって特徴付けられています.
研究 の 目的:
- HFpEFにおける心筋線維症と左心房 (LV) 縮の病理生理学的役割を検討する.
- これらの状態の現在の診断方法を概説します.
- HFpEFにおける線維症と高縮症を標的とした新しい治療戦略について議論する.
主な方法:
- HFpEFの病理生理学,診断,治療に重点を置いた文献レビュー.
- 併発症が心臓の改造に及ぼす影響の分析
- 新しい治療方法の検討
主要な成果:
- 併発性疾患はHFpEFにおける不良心改造と心筋線維症に寄与する.
- 心筋線維症と心筋縮症は,腹動力機能不全,充填圧の上昇,運動耐性の低下,不良の予後につながる.
- 現在の治療法では,HFpEFの繊維症と過剰増殖に対処する特定のメカニズムが欠けている.
結論:
- HFpEFの病原性において,心筋線維症とLV高縮症は決定的なものです.
- これらを重要な特徴として認識することで 標的治療の開発を導くことができます
- 将来の臨床試験では,線維症と縮を直接調節する戦略に焦点を当てるべきです.
関連する概念動画
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:29Heart Failure II: Pathophysiology
37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
01:29Cardiomyopathy V: Interprofessional Care
32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
01:17Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505